Got denied? You're not alone, and "no" often isn't final.
A new Medscape report put numbers to something so many of you have lived: 85% of GLP-1 prescriptions for weight loss are initially denied by insurance, and most people never appeal. Only about 1 in 10 denials gets challenged.
Here's the part that matters: when appeals are done right, 40-50% get overturned. One doctor in the piece handles 40 appeals a week with a 50% success rate. The difference is usually documentation: weight records, history, the right language in the letter, and persistence.
What this means for you: A denial letter is the start of a process, not the end of the road. If this happens to you, don't quietly give up. It's what the system is counting on.
→ Raise with your prescriber: "Can we appeal this? What documentation would strengthen it?" Some practices have staff who do nothing but prior authorizations. Ask if yours does.
Source: Medscape Medical News, October 2026
GLP-1s and mood: a hopeful headline, read carefully.
A large Swedish study of 95,000 people, published in The Lancet Psychiatry, found that periods on GLP-1 medications were linked to a 42% lower risk of worsening depression and anxiety, plus fewer hospitalizations and less sick leave.
Promising? Yes. But read the fine print with me: this was an observational study, which means it shows a link, not proof of cause. The researchers themselves say it's too soon to consider GLP-1s a treatment for mental health conditions.
What this means for you: Your mental health is part of this journey, not separate from it. If you've noticed your mood shifting, either direction, since starting, that's worth paying attention to and worth mentioning.
→ Raise with your prescriber: Any mood changes, good or bad, belong in the conversation at your next visit. This is a "bring the full picture" moment.
Source: Healthline, March 2026 (study: The Lancet Psychiatry)
The long-term picture: the good, the bad, and the muscle question.
Healthline rounded up what we know about long-term GLP-1 use. The good: strong evidence for heart, kidney, and metabolic benefits. The bad: rare but real risks worth knowing about: gallbladder issues, severe digestive slowing, and eye complications for people with existing retinopathy.
And then there's the part I won't stop talking about: you don't just lose fat, you lose muscle and bone density too, which means less strength and more frailty risk as you age. Doctors in the piece urge resistance training alongside the medication.
What this means for you: This is the "it's not what you lose, it's what you keep" story in medical journals. The medication handles appetite. You handle the muscle: with protein, with strength work, with habits. That's the part no prescription covers.
→ Raise with your prescriber: Ask what monitoring makes sense for you long-term. That's their department. The strength plan is mine.
Source: Healthline, 2026
That's this week in GLP-1 news, translated. The headlines will keep coming — I'll keep telling you what they actually mean for your life. 💛
— Suzette
